Showing 5721-5730 of 8206 results for "".
- Evommune Initiates Phase 1 Study of EVO101 for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/evommune-initiates-phase-1-study-of-evo101-for-inflammatory-skin-diseases/2461117/Evommune, Inc. has enrolled the first participant in its Phase 1 study of EVO101 in healthy volunteers. EVO101 is a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) which broadly inhibits innate inflammation and is being
- Aquaphor Unveils New Purpose-Driven Brand Campaignhttps://practicaldermatology.com/news/aquaphor-unveils-new-purpose-driven-brand-campaign/2461099/Aquaphor is launching its first-ever brand purpose campaign, "Before & Aquaphor." Inspired by the growing field of psychodermatology, this new integrated campaign highlights the connection between our skin health and our emotional well-being.
- The National Eczema Association and Pediatric Dermatology Research Alliance Receive Collaborative Engagement Award from PCORIhttps://practicaldermatology.com/news/the-national-eczema-association-and-pediatric-dermatology-research-alliance-receive-collaborative-engagement-award-from-pcori/2461041/The
- $511M SPAC Deal for Sunevahttps://practicaldermatology.com/news/511m-spac-deal-for-suneva/2461032/Suneva Medical, Inc. and Viveon Health Acquisition Corp., a special purpose acquisition company (SPAC), are joining forces to form a regenerative aesthetics company. Upon completion of the transaction, the combined company's securities are expected to be traded on the NYSE unde
- DermBiont Acquires Chromadermhttps://practicaldermatology.com/news/dermbiont-acquires-chromaderm/2461017/
- Otezla Becomes First Oral Psoriasis Treatment Approved Across All Disease Severitieshttps://practicaldermatology.com/news/otezla-becomes-first-oral-psoriasis-treatment-approved-across-all-disease-severities/2461014/Otezla® (apremilast) from Amgen is now approved for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. This expanded indication makes Otezla the first and only oral treatment approved 
- Dr. Jennifer Schoch Wins NEA/PeDRA 2021 Childhood Eczema Challenge Granthttps://practicaldermatology.com/news/dr-jennifer-schoch-wins-neapedra-2021-childhood-eczema-challenge-grant/2460878/The National Eczema Association (NEA) and the
- StrataGraft Reduces Need for Autografting of Deep Partial-Thickness Burnshttps://practicaldermatology.com/news/stratagraft-reduces-need-for-autografting-of-deep-partial-thickness-burns-strata/2460858/
- Mindera Platform Named MedTech’s “Best New Technology Solution for Dermatology"https://practicaldermatology.com/news/mindera-platform-named-medtechs-best-new-technology-solution-for-dermatology/2460799/
- DermTech Launches New Campaign to Bring Awareness to Need for Skin Cancer Skin Examshttps://practicaldermatology.com/news/dermtech-launches-new-campaign-to-bring-awareness-to-need-for-skin-cancer-skin-exams/2460793/To honor May as Melanoma and Skin Cancer Awareness Month,